Cargando…

Angiotensin II receptor blockers and risk of acute pancreatitis - a population based case–control study in Sweden

BACKGROUND: Acute pancreatitis is a potentially lethal disease, with a rising incidence in the Western world. Yet, no pharmacological prevention or specific treatment for acute pancreatitis exists. Also, the connection with severity of acute pancreatitis is unknown. Experimental and epidemiological...

Descripción completa

Detalles Bibliográficos
Autores principales: Bexelius, Tomas S., Ljung, Rickard, Mattsson, Fredrik, Lu, Yunxia, Lindblad, Mats
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5341438/
https://www.ncbi.nlm.nih.gov/pubmed/28270103
http://dx.doi.org/10.1186/s12876-017-0595-8
_version_ 1782512990370660352
author Bexelius, Tomas S.
Ljung, Rickard
Mattsson, Fredrik
Lu, Yunxia
Lindblad, Mats
author_facet Bexelius, Tomas S.
Ljung, Rickard
Mattsson, Fredrik
Lu, Yunxia
Lindblad, Mats
author_sort Bexelius, Tomas S.
collection PubMed
description BACKGROUND: Acute pancreatitis is a potentially lethal disease, with a rising incidence in the Western world. Yet, no pharmacological prevention or specific treatment for acute pancreatitis exists. Also, the connection with severity of acute pancreatitis is unknown. Experimental and epidemiological research suggests a protective effect of angiotensin II receptor blockers. METHODS: During 2006 to 2008, we performed a nationwide case–control study on Swedish residents aged 40–84 years. First-time cases with acute pancreatitis were identified in the National Patient Register and data on dispensed prescriptions was retrieved from the Prescribed Drug Register. Controls were randomly selected from the general population in Sweden frequency-matched on sex, age, and calendar year. To estimate relative risk of acute pancreatitis, by degree of severity, among users of angiotensin II receptor blockers, as compared to non-users, we used multivariable logistic regression analysis to calculate odds ratios (OR) with 95% confidence interval (CI). RESULTS: Among 6,161 cases of acute pancreatitis and 61,637 controls, current use of angiotensin II receptor blockers was followed by a decreased risk of acute pancreatitis, compared to non-users, adjusted OR 0 · 77 (95% CI 0 · 69–0 · 86). No protective association, but an increased risk was found for users of angiotensin-converting enzyme inhibitors (adjusted OR 1 · 11, 95% CI: 1 · 01–1 · 21), analysed for comparison reasons. There was a significant decreased risk associated with both severe acute pancreatitis, (OR 0 · 71 (0 · 59–0 · 85), and mild acute pancreatitis; adjusted OR 0 · 81 (0 · 70–0 · 94). CONCLUSION: This population-based case–control study indicates that use of angiotensin II receptor blockers might be associated with a lesser risk of acute pancreatitis, and that the protective association was significant among cases of both severe and mild acute pancreatitis. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12876-017-0595-8) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-5341438
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-53414382017-03-10 Angiotensin II receptor blockers and risk of acute pancreatitis - a population based case–control study in Sweden Bexelius, Tomas S. Ljung, Rickard Mattsson, Fredrik Lu, Yunxia Lindblad, Mats BMC Gastroenterol Research Article BACKGROUND: Acute pancreatitis is a potentially lethal disease, with a rising incidence in the Western world. Yet, no pharmacological prevention or specific treatment for acute pancreatitis exists. Also, the connection with severity of acute pancreatitis is unknown. Experimental and epidemiological research suggests a protective effect of angiotensin II receptor blockers. METHODS: During 2006 to 2008, we performed a nationwide case–control study on Swedish residents aged 40–84 years. First-time cases with acute pancreatitis were identified in the National Patient Register and data on dispensed prescriptions was retrieved from the Prescribed Drug Register. Controls were randomly selected from the general population in Sweden frequency-matched on sex, age, and calendar year. To estimate relative risk of acute pancreatitis, by degree of severity, among users of angiotensin II receptor blockers, as compared to non-users, we used multivariable logistic regression analysis to calculate odds ratios (OR) with 95% confidence interval (CI). RESULTS: Among 6,161 cases of acute pancreatitis and 61,637 controls, current use of angiotensin II receptor blockers was followed by a decreased risk of acute pancreatitis, compared to non-users, adjusted OR 0 · 77 (95% CI 0 · 69–0 · 86). No protective association, but an increased risk was found for users of angiotensin-converting enzyme inhibitors (adjusted OR 1 · 11, 95% CI: 1 · 01–1 · 21), analysed for comparison reasons. There was a significant decreased risk associated with both severe acute pancreatitis, (OR 0 · 71 (0 · 59–0 · 85), and mild acute pancreatitis; adjusted OR 0 · 81 (0 · 70–0 · 94). CONCLUSION: This population-based case–control study indicates that use of angiotensin II receptor blockers might be associated with a lesser risk of acute pancreatitis, and that the protective association was significant among cases of both severe and mild acute pancreatitis. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12876-017-0595-8) contains supplementary material, which is available to authorized users. BioMed Central 2017-03-07 /pmc/articles/PMC5341438/ /pubmed/28270103 http://dx.doi.org/10.1186/s12876-017-0595-8 Text en © The Author(s). 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Bexelius, Tomas S.
Ljung, Rickard
Mattsson, Fredrik
Lu, Yunxia
Lindblad, Mats
Angiotensin II receptor blockers and risk of acute pancreatitis - a population based case–control study in Sweden
title Angiotensin II receptor blockers and risk of acute pancreatitis - a population based case–control study in Sweden
title_full Angiotensin II receptor blockers and risk of acute pancreatitis - a population based case–control study in Sweden
title_fullStr Angiotensin II receptor blockers and risk of acute pancreatitis - a population based case–control study in Sweden
title_full_unstemmed Angiotensin II receptor blockers and risk of acute pancreatitis - a population based case–control study in Sweden
title_short Angiotensin II receptor blockers and risk of acute pancreatitis - a population based case–control study in Sweden
title_sort angiotensin ii receptor blockers and risk of acute pancreatitis - a population based case–control study in sweden
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5341438/
https://www.ncbi.nlm.nih.gov/pubmed/28270103
http://dx.doi.org/10.1186/s12876-017-0595-8
work_keys_str_mv AT bexeliustomass angiotensiniireceptorblockersandriskofacutepancreatitisapopulationbasedcasecontrolstudyinsweden
AT ljungrickard angiotensiniireceptorblockersandriskofacutepancreatitisapopulationbasedcasecontrolstudyinsweden
AT mattssonfredrik angiotensiniireceptorblockersandriskofacutepancreatitisapopulationbasedcasecontrolstudyinsweden
AT luyunxia angiotensiniireceptorblockersandriskofacutepancreatitisapopulationbasedcasecontrolstudyinsweden
AT lindbladmats angiotensiniireceptorblockersandriskofacutepancreatitisapopulationbasedcasecontrolstudyinsweden